Are you ready for the mandatory transition to eCTD for prescription medicines?
A staged implementation has been proposed for prescription medicines to reflect the current industry uptake of the eCTD format. The transition begins with new chemical entity, new biological entity, biosimilar…
The long road to PBS listing for Orkambi
With its recent stint on Sunrise, Orkambi is a high-profile example of what can occur when both the PBAC and the sponsor are unable to reach agreement on the value of a…
New ‘SmPC’ Format for the Australian Product Information
The TGA have published a new form for providing the product information (PI) which means more work for regulatory teams but an enhancement of the quality use of medicines for Australian patients….
Commercial Eyes has a Victorian Poisons and Controlled Substances Licence
The licence facilitates our Regulatory Services department’s product complaints investigations work and enables our Medical Services team to reference the physical product when responding to medical enquiries from patients and…
FDA tick of approval: Commercial Eyes’ Drug Safety Group has been successfully audited by the FDA!
Local pharma expertise and know how: why you need it
Entering a new marketplace – whether for a medicine, a cosmetic, a device or a complementary medicine – is challenging, time consuming, expensive and often just difficult….
PharmaDispatch: Commercial Eyes founder wins Pat Clear Award
Commercial Eyes’ Managing Director, Andrew Carter, features in today’s issue of…
Andrew Carter – 2014 Pat Clear Award recipient
Andrew Carter is recipient of the 2014 recipient of the Pat Clear Award, Australian medicine industry’s most prestigious…
Commercial Eyes is green through and through
At Commercial Eyes, we believe we have a responsibility to care for and protect the environment. We’ve been committed to improving our environmental performance for many years and are delighted…